Ligand id: 9758

Name: camrelizumab

No information available.
Summary of Clinical Use
More than 20 clinical trials assessing camrelizumab's anti-tumour activity are registered with The most advanced trials are two Phase 3 clinical trials evaluating camrelizumab's efficacy against lung cancer (NCT03134872) and esophageal carcinoma (NCT03099382). The first global approval of camrelizumab was granted by China in 2019, under which camrelizumab is indicated as a treatment for relapsed/refractory classical Hodgkin lymphoma [1].